Clinical trials: Resistant Major Depression
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
- Trial name
- NORLIGHT (NCT07284667)
- Testing
- ACP-211
- Where
- 28 sites in United States
- Volunteers
- 153 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Treatment Resistant Depression, Inflammation
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard…
- Conditions
- Treatment Resistant Depression, Inflammation, Overweight
- Trial name
- NCT05774665
- Testing
- Omega 3
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NESBID: Neuro-Stimulation of the Brain in Depression
In Canada, approximately 20% of patients with Major Depressive Disorder (MDD) have treatment-resistance and fail to respond to trials of pharmacotherapy or psychotherapy.
- Conditions
- Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Transcranial Direct Current Stimulation, Electric Stimulation Therapy
- Trial name
- NESBID (NCT04159012)
- Testing
- Transcranial direct current stimulation
- Where
- Canada
- Sponsor
- University of Alberta
Transcranial Magnetic Stimulation, Repetitive, Depression - Major Depressive Disorder
Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.
The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS…
- Trial name
- TMS-DEP-2024 (NCT07207239)
- Testing
- repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol
- Where
- Hungary
- Volunteers
- 54 people
- Sponsor
- Semmelweis University
Depression, Unipolar, Treatment Resistant Depression
PF-04995274 and Emotional Processing in Treatment Resistant Depression
This study will test whether seven days adjunctive administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and non-emotional cognition in medicated…
- Trial name
- RESTART (NCT03515733)
- Testing
- PF-04995274
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- University of Oxford
Resistant Major Depression
Pentoxifylline for Treatment of Resistant Major Depression
A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders.
- Trial name
- NCT05324735
- Testing
- Pentoxifylline
- Where
- Iraq
- Volunteers
- 60 people
- Sponsor
- Hawler Medical University
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression
Transcranial direct current stimulation (tDCS) is a noninvasive method to activate or de-activate neurons in superficial regions of the brain through the induction of weak electric currents in the brain tissue delivered by two…
- Trial name
- NCT01450150
- Testing
- Transcranial Direct Current Stimulation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Douglas Mental Health University Institute
Depression, Depressive Disorder
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
To evaluate the equivalent efficacy of ultrabrief pulsewidth right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy in the treatment of depression and to evaluate the cognitive effects…
- Conditions
- Depression, Depressive Disorder, Treatment Resistant Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02238730
- Testing
- Ultrabrief Right Unilateral, Brief Pulse Bitemporal
- Sponsor
- Kaiser Permanente
Major Depressive Disorder
Feasibility of Resistance Exercise to Treat Major Depression Via Cerebrovascular Mechanisms
This project is a single-arm pilot trial to investigate the feasibility, acceptability, and plausible efficacy of a 16-week resistance exercise training (RET) program for treatment of major depressive disorder.
- Trial name
- NCT05695365
- Testing
- Resistance Exercise Training
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Iowa State University
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Depression
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued Duloxetine/Escitalopram in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01369095
- Testing
- Duloxetine, Escitalopram, BMS-820836
- Where
- 93 sites in United States, Argentina and 10 more
- Volunteers
- 976 people
- Sponsor
- Bristol-Myers Squibb
Depressive Disorder, Major
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects…
- Trial name
- NCT03027362
- Testing
- Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Yale University
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Treatment-Resistant Major Depressive Disorder
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
- Trial name
- NCT05381974
- Testing
- Psilocybin
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Major Depression Disorder
DBS of the Habenula for Treatment- Resistant Major Depression
The habenula(Hb) is an epithalamic structure located at the center of the dorsal diencephalic conduction system, a pathway involved in linking forebrain to midbrain regions.
- Trial name
- NCT03347487
- Testing
- Deep brain stimuation system implantation
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Ruijin Hospital
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Treatment Resistant Depression, Depression
Glutamate Emotion Memory Study
Clinical depression often includes a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or looking forward to things.
- Conditions
- Treatment Resistant Depression, Depression, Major Depressive Disorder
- Trial name
- GEMS (NCT05809609)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford